Medtronic has recently received CE mark approval and Food and Drug Administration clearance for its LINQ 2 insertable cardiac monitor (ICM) with remote programming, which allows clinicians to optimise device settings without the need for patients to return to the hospital or office.
The LINQ 2 system, which is one-third of the size of a triple-A battery, aims to deliver enhanced precision to accurately detect abnormal heart rhythms and last four and a half years.
“Medtronic receives CE mark approval and FDA clearance for its LINQ 2 insertable cardiac monitor.“
Chief Medical Officer of the Cardiac Rhythm and Heart Failure division – part of the Cardiac and Vascular Group, Medtronic, Rob Kowal, stated: “In the current COVID-19 environment, the LINQ 2 system offers patients a seamless way to experience ongoing connectivity between their device and their physician while reducing the need for in office visits. LINQ 2 gives physicians actionable data to help diagnose underlying heart conditions and define treatment protocols for patients with atrial fibrillation or other abnormal heart rhythms.”